There is a lot of noise in the world of genetics. Direct-to-consumer ads suggest testing for everything from wellness to ancestry, but in clinical practice, genetic testing is reserved for specific scenarios:

• To confirm a diagnosis,
• To change screening,
• To guide treatment, or
• To protect family members through cascade testing.

At HealthCode Gene, we believe in Evidence Over Hype . Based on current clinical practice guidelines (NCCN, CPIC, ACMG, ACOG, ACC/AHA, KDIGO) and widely used clinical pathways, we have compiled the Top 10 Evidence-Based Indications for genetic testing.

This isn't about curiosity. It's about actionable health decisions.

The CMeM-4™ Framework

Before we dive in, understand how we analyze every indication:

•  Context: Who is this for?
• Mechanism: What biological pathway is involved?
• Evidence: What do the guidelines say?
• Key Genes: Which specific variants are we looking at?
• What to Do Next: How does this change your health plan?

1. Hereditary Cancer Risk

Context: Diagnosis of cancer before age 50, multiple family members with related cancers, rare cancers (ovarian, pancreatic, male breast), or Ashkenazi Jewish ancestry.

Mechanism: Defects in DNA repair pathways (Homologous Recombination, Mismatch Repair).

Evidence: NCCN guidelines outline criteria for genetic/familial high-risk assessment and multigene panel testing when appropriate. (NCCN High-Risk Assessment Guidelines)

Key Genes: BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, PALB2, TP53.

What to Do Next: Collect family history (who, what cancer, what age). If patterns fit, ask for genetics referral rather than buying a random panel.

2. Pharmacogenomics (PGx) – Medication Safety

Context: Patients experiencing severe side effects, or lack of efficacy after trying 2+ standard medications (e.g., antidepressants, painkillers, statins).

Mechanism: Variants in Cytochrome P450 enzymes affect drug metabolism (Poor, Intermediate, Normal, Ultrarapid metabolizers).

Evidence: CPIC provides evidence-based guidance on how to use pharmacogenetic results when they are available, and the FDA lists pharmacogenomic biomarkers across many drug labels. ( CPIC Guidelines ,  FDA PGx Biomarkers in Drug Labeling)

Key Genes: CYP2D6, CYP2C19, CYP2C9, VKORC1, TPMT, DPYD.

What to Do Next: If considering PGx, do it through clinical care where medication history, other meds, and symptoms are integrated.

3. Familial Hypercholesterolemia (FH)

Context: Untreated LDL cholesterol >190 mg/dL in adults, or premature coronary artery disease (men <55, women <65) in family.

Mechanism: Impaired LDL receptor clearance leading to lifelong high cholesterol.

Evidence: FH is a CDC “Tier 1” genomic application with clear public health benefit, and cascade screening is widely recommended in clinical pathways. (CDC Tier 1 Genomics,  CDC FH Toolkit)

Key Genes: LDLR, APOB, PCSK9.

What to Do Next: Don't start with PRS. Start with lipids + family history; ask about FH clinical criteria and genetics if suspected.

4. Connective Tissue Disorders (Aortic Risk)

Context: Personal or family history of aortic aneurysm/dissection, Marfan syndrome features (tall stature, lens dislocation), or sudden cardiac death.

Mechanism: Structural weakness in connective tissue (fibrillin, collagen, TGF-beta pathways).

Evidence: ACC/AHA aortic disease guidance supports genetic evaluation and family screening when heritable thoracic aortic disease is suspected. (2022 ACC/AHA Aortic Disease Guideline (PubMed))

Key Genes: FBN1, TGFBR1, TGFBR2, ACTA2, COL3A1.

What to Do Next: If there's a red flag family history, the first step is a cardiology workup + genetic counseling, not direct-to-consumer testing.

5. Neurodevelopmental Disorders (ID/DD/ASD)

Context: Unexplained global developmental delay, intellectual disability, autism spectrum disorder with dysmorphic features, or multiple congenital anomalies.

Mechanism: Chromosomal imbalances or single-gene variants affecting neurodevelopment.

Evidence: ACMG supports exome/genome sequencing for many children with congenital anomalies/developmental delay/intellectual disability; CMA and targeted testing may still be used depending on clinical context. (ACMG ES/GS Guideline (PubMed),  AAP: Genetic Evaluation of ID (Pediatrics))

Key Tests: CMA, FMR1 (Fragile X), MECP2, WES.

What to Do Next: Discuss referral to clinical genetics; test choice and consent matter a lot here.

6. Carrier Screening (Preconception/Prenatal)

Context: All individuals planning pregnancy or currently pregnant (pan-ethnic recommendation).

Mechanism: Autosomal recessive or X-linked conditions where parents are healthy carriers.

Evidence: ACOG supports carrier screening approaches in genomic medicine, and ACMG provides tiered practice resources for carrier screening. (ACOG Carrier Screening, ACMG Carrier Screening Tiers (GIM))

Key Conditions: Cystic Fibrosis (CFTR), Spinal Muscular Atrophy (SMN1), Hemoglobinopathies, Fragile X.

What to Do Next: Ask for genetic counseling to understand what's testable and what choices the information would enable.

7. Recurrent Pregnancy Loss (RPL)

Context: ≥2 unexplained clinical miscarriages.

Mechanism: Chromosomal abnormalities in the embryo (often due to parental balanced translocations).

Evidence: ASRM provides guidance on evaluation and treatment of RPL; ACOG guidance cautions against routine thrombophilia testing for pregnancy loss without appropriate clinical context. (ASRM RPL Committee Opinion,  ACOG PB 197 (Inherited Thrombophilias)

Key Tests: Parental Karyotypes, Products of Conception (POC) Chromosomal Analysis.

What to Do Next: This is standard genetics practice: targeted/cascade testing is most efficient when there's an established familial finding.

8. Hereditary Kidney Disease

Context: Early-onset Chronic Kidney Disease (CKD), family history of kidney failure, or syndromic features (hearing loss, cysts).

Mechanism: Structural or functional defects in kidney filtration units.

Evidence: KDIGO provides guideline resources for ADPKD and emphasizes structured evaluation; genetics can guide diagnosis and family risk assessment in appropriate cases. (KDIGO 2025 ADPKD Guideline (PDF))

Key Genes: PKD1, PKD2 (ADPKD), COL4A3-5 (Alport), UMOD.

What to Do Next: This is where "clinical-grade interpretation" matters most — symptoms, labs, imaging, and family history should drive analysis.

9. Sudden Cardiac Death Risk (Channelopathies/Cardiomyopathy)

Context: Unexplained syncope (fainting), seizure-like episodes, family history of sudden death <40, or abnormal ECG.

Mechanism: Electrical ion channel defects or structural heart muscle abnormalities.

Evidence: Multisociety cardiology guidance supports genetic evaluation/testing in inherited cardiomyopathies/arrhythmia syndromes to confirm diagnosis and enable cascade screening. (AHA/ACC HCM Guideline (2024))

Key Genes: KCNQ1, KCNH2, SCN5A (Long QT); MYH7, MYBPC3 (HCM).

What to Do Next: If there's a red flag family history, the first step is a cardiology workup + genetic counseling, not direct-to-consumer testing.

10. Rare/Undiagnosed Disease (Whole Exome/Genome)

Context: Years of symptoms without a diagnosis, multiple system involvement, rare conditions.

Mechanism: Rare variants not covered by standard panels.

Evidence: ACMG supports ES/GS in appropriate undiagnosed presentations where standard testing has not yielded a diagnosis. ACMG ES/GS Guideline (PubMed)

Key Tests: Whole Exome Sequencing (WES), Whole Genome Sequencing (WGS).

What to Do Next: This is where "clinical-grade interpretation" matters most — symptoms, labs, imaging, and family history should drive analysis.

⚠️ What We Do NOT Recommend (Evidence-Based)

•  MTHFR Testing: Not recommended for thrombosis, pregnancy loss, or CVD risk (ACMG). ACMG statement (MTHFR)
• Routine Thrombophilia Panels for RPL: Not recommended without appropriate clinical context (ACOG). ACOG PB 197
• APOE for Alzheimer's Screening: Not generally recommended for asymptomatic risk prediction due to limited clinical actionability. Review on APOE testing limitations
• Direct-to-Consumer "Wellness" Panels: Often lack clinical validation and actionable guidance (compare against guideline-based testing pathways).

Conclusion: Testing is Data. Modelling is Action.

Knowing you have a variant is only the first step. At HealthCode Gene, we apply the CMeM-4™ Framework to turn that data into a personalized health model.

🧮 Try the  genetic testing Calculator

Unsure if genetic testing is for you?  Take a 2 min assessment  using our live genetic testing calculator

         🧮 Try the Calculator

References 

•  NCCN: Genetic/Familial High-Risk Assessment (Breast/Ovarian/Pancreatic/Prostate)
• CPIC: Pharmacogenetics Clinical Practice Guidelines
• FDA: Table of Pharmacogenomic Biomarkers in Drug Labeling
• CDC: Tier 1 Genomic Applications (HBOC, Lynch, FH)
• CDC: Familial Hypercholesterolemia Toolkit
• ACC/AHA (2022): Aortic Disease Guideline (PubMed)
• ACMG (2021): Exome/Genome Sequencing for CA/DD/ID (PubMed)
• AAP (2025): Genetic Evaluation of the Child With Intellectual Disability (Pediatrics)
• ACOG: Carrier Screening in the Age of Genomic Medicine
• ASRM: Evaluation and Treatment of Recurrent Pregnancy Loss (Committee Opinion)
• ACOG Practice Bulletin 197: Inherited Thrombophilias
• KDIGO (2025): ADPKD Guideline (PDF)
• AHA/ACC (2024): Hypertrophic Cardiomyopathy Guideline
• ACMG: MTHFR Polymorphism Testing Is Not Clinically Indicated
• APOE Testing: Limitations for Predictive Screening (Review)